|
Syncona Ltd on Tuesday noted half-year results of its investees, Freeline Therapeutics Holdings PLC and Achilles Therapeutics PLC.
Syncona is a London-based investor in healthcare companies.
Freeline's interim pre-tax loss to June 30 narrowed to $51.0 million from $74.8 million a year ago.
Research & development costs narrowed to $38.8 million from $48.1 million. General and administrative expenses fell to $16.3 million from $24.6 million.
Freeline expects to update on three phase 1/2 trials on three diseases in the second half of 2022. Those include a dose-finding trial of FLT190 in Fabry disease, a dose-finding trial of FLT201 in Gaucher disease and efficacy data from a dose-confirmation trial of FLT180a in haemophilia B. The firm aims to release efficacy data on its Gaucher disease trial in the first half of 2023.
Meanwhile, Achilles' interim pretax loss to June 30 widened to $34.6 million from $29.9 million the prior year.
Research & development costs increased to $27.8 million from $19.7 million.
Achilles expects to provide initial data on a Phase 1/2a trial of its T cell therapy in non-small cell lung cancer and melanoma in the fourth quarter of 2022.
Syncona added that Achilles' cash balance of $202 million is able ‘to support all planned operations into the second quarter of 2025, including completion of its ongoing Phase 1/2a clinical trials’.
Syncona shares were flat at 207.50 pence each in London on Tuesday afternoon.
Copyright 2022 Alliance News Limited. All Rights Reserved.
|
